Comparative Pharmacology
Head-to-head clinical analysis: BUTABARBITAL versus SODIUM PENTOBARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARBITAL versus SODIUM PENTOBARBITAL.
BUTABARBITAL vs SODIUM PENTOBARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing inhibitory neurotransmission. At high doses, it acts as a GABA mimetic and depresses neuronal excitability.
50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.
IV: 100-150 mg administered over 1-2 minutes for induction of anesthesia; for seizure control, 100 mg IV every 5-10 minutes up to 500 mg. For maintenance of anesthesia, 50 mg IV as needed every 15-30 minutes. IM: 150-200 mg for preoperative sedation.
None Documented
None Documented
Clinical Note
moderateButabarbital + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate."
Clinical Note
moderateButabarbital + Haloperidol
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol."
Clinical Note
moderateButabarbital + Clemastine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine."
Clinical Note
moderateTerminal elimination half-life is 30-50 hours in adults, which may be prolonged in elderly or patients with hepatic impairment, leading to accumulation with repeated dosing.
15-50 hours (dose-dependent; prolonged in hepatic impairment).
Primarily renal, with approximately 60-80% of the dose eliminated as metabolites (mostly hydroxylated and conjugated) and less than 5% as unchanged drug. Minor biliary/fecal excretion occurs (<10%).
Renal (25-50% unchanged); hepatic metabolism to inactive metabolites; fecal <5%.
Category C
Category D/X
Barbiturate
Barbiturate
Butabarbital + Venlafaxine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine."